arbiter
JournalsPricingAccount

Modeling the cost-effectiveness of the next-generation COVID-19 mRNA-1283 vaccine in the United States

K Fust et al.

Journal of Medical Economics2026https://doi.org/10.1080/13696998.2026.2624967article
ABDC C
Weight
0.37

What the paper says

Study results suggest mRNA-1283 may represent a highly cost-effective strategy (considering a $100,000-150,000 per QALY willingness-to-pay threshold) to reduce COVID-19 burden. Based on rVE assumptions made, mRNA-1283 was estimated to dominate originally-licensed mRNA vaccines in this recommended population. mRNA-1283 may provide a valuable option to optimize US COVID-19 immunization programs and protect those most vulnerable.

1 citation

Open paper page →

Cite this paper

https://doi.org/https://doi.org/10.1080/13696998.2026.2624967

Or copy a formatted citation

@article{k2026,
  title        = {{Modeling the cost-effectiveness of the next-generation COVID-19 mRNA-1283 vaccine in the United States}},
  author       = {K Fust et al.},
  journal      = {Journal of Medical Economics},
  year         = {2026},
  doi          = {https://doi.org/https://doi.org/10.1080/13696998.2026.2624967},
}

Paste directly into BibTeX, Zotero, or your reference manager.

Flag this paper

Modeling the cost-effectiveness of the next-generation COVID-19 mRNA-1283 vaccine in the United States

Flags are reviewed by the Arbiter methodology team within 5 business days.

Evidence weight

0.37

Balanced mode · F 0.40 / M 0.15 / V 0.05 / R 0.40

F · citation impact0.16 × 0.4 = 0.06
M · momentum0.53 × 0.15 = 0.08
V · venue signal0.50 × 0.05 = 0.03
R · text relevance †0.50 × 0.4 = 0.20

† Text relevance is estimated at 0.50 on the detail page — for your query’s actual relevance score, open this paper from a search result.